US2019262423A1PendingUtilityA1
Activin-actrii antagonists and uses for treating bone and other disorders
Est. expiryNov 2, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 3/14A61P 3/12A61P 9/10A61P 9/14A61P 13/12A61P 19/08A61P 19/10A61K 38/1796A61K 38/179
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-Act-RIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.
Claims
exact text as granted — not AI-modified1 . A method for (i) treating an adynamic bone disorder in a subject, (ii) treating an adynamic bone disorder form of CKD-MBD in a subject, (iii) treating a low bone turnover form of CKD-MBD in a subject, (iv) treating a bone disorder characterized by hyperphosphatemia in a subject, or (v) treating a renal disease in a subject, wherein the method comprises administering a therapeutically effective amount of an ActRII inhibitor to a subject in need of such treatment.
2 . (canceled)
3 . The method of claim 1 , wherein the adynamic bone disorder is characterized by absence of tetracycline incorporation into mineralized bone.
4 . (canceled)
5 . The method of claim 1 , wherein the low bone turnover form of CKD-MBD is osteomalacia.
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . The method of claim 1 , wherein the renal disease is renal fibrosis.
10 . A method for reducing vascular calcium levels in a subject diagnosed with vascular calcification, wherein the method comprises administering a therapeutically effective amount of an ActRII inhibitor to the subject.
11 . The method of claim 1 wherein the ActRII inhibitor is a polypeptide comprising an amino acid sequence selected from the group consisting of:
a. 90% identical to SEQ ID NO:2;
b. 95% identical to SEQ ID NO:2;
c. 98% identical to SEQ ID NO:2;
d. SEQ ID NO:2;
e. 90% identical to SEQ ID NO:3;
f 95% identical to SEQ ID NO:3;
g. 98% identical to SEQ ID NO:3;
h. SEQ ID NO:3;
i. 90% identical to SEQ ID NO:6;
j. 95% identical to SEQ ID NO:6;
k. 98% identical to SEQ ID NO:6;
l. SEQ ID NO:6;
m. 90% identical to SEQ ID NO:7;
n. 95% identical to SEQ ID NO:7;
o. 98% identical to SEQ ID NO:7;
p. SEQ ID NO:7;
q. 90% identical to SEQ ID NO:12;
r. 95% identical to SEQ ID NO:12;
s. 98% identical to SEQ ID NO:12;
t. SEQ ID NO:12;
u. 90% identical to SEQ ID NO:17;
v. 95% identical to SEQ ID NO:17;
w. 98% identical to SEQ ID NO:17;
x. SEQ ID NO:17;
y. 90% identical to SEQ ID NO:20;
z. 95% identical to SEQ ID NO:20;
aa. 98% identical to SEQ ID NO:20;
bb. SEQ ID NO:20;
cc. 90% identical to SEQ ID NO:21;
dd. 95% identical to SEQ ID NO:21;
ee. 98% identical to SEQ ID NO:21;
ff. SEQ ID NO:21
gg. 90% identical to SEQ ID NO:23;
hh. 95% identical to SEQ ID NO:23;
ii. 98% identical to SEQ ID NO:23;
jj. SEQ ID NO:23
kk. 90% identical to SEQ ID NO:25;
ll. 95% identical to SEQ ID NO:25;
mm. 98% identical to SEQ ID NO:25; and
nn. SEQ ID NO:25.
12 . The method of claim 1 , wherein the ActRII inhibitor is a polypeptide comprising the amino acid sequence of SEQ ID NO:7.
13 . The method of claim 1 , wherein the ActRII inhibitor is administered parentally.
14 . The method of claim 1 , wherein the subject is less than 18 years old.
15 . The method of claim 1 , wherein the method increases the height of the subject.
16 . The method of claim 1 , wherein the subject has end stage renal disease.
17 . The method of claim 1 , wherein the subject undergoes dialysis.
18 . The method of claim 10 wherein the ActRII inhibitor is a polypeptide comprising an amino acid sequence selected from the group consisting of:
a. 90% identical to SEQ ID NO:2;
b. 95% identical to SEQ ID NO:2;
c. 98% identical to SEQ ID NO:2;
d. SEQ ID NO:2;
e. 90% identical to SEQ ID NO:3;
f 95% identical to SEQ ID NO:3;
g. 98% identical to SEQ ID NO:3;
h. SEQ ID NO:3;
i. 90% identical to SEQ ID NO:6;
j. 95% identical to SEQ ID NO:6;
k. 98% identical to SEQ ID NO:6;
l. SEQ ID NO:6;
m. 90% identical to SEQ ID NO:7;
n. 95% identical to SEQ ID NO:7;
o. 98% identical to SEQ ID NO:7;
p. SEQ ID NO:7;
q. 90% identical to SEQ ID NO:12;
r. 95% identical to SEQ ID NO:12;
s. 98% identical to SEQ ID NO:12;
t. SEQ ID NO:12;
u. 90% identical to SEQ ID NO:17;
v. 95% identical to SEQ ID NO:17;
w. 98% identical to SEQ ID NO:17;
x. SEQ ID NO:17;
y. 90% identical to SEQ ID NO:20;
z. 95% identical to SEQ ID NO:20;
aa. 98% identical to SEQ ID NO:20;
bb. SEQ ID NO:20;
cc. 90% identical to SEQ ID NO:21;
dd. 95% identical to SEQ ID NO:21;
ee. 98% identical to SEQ ID NO:21;
ff. SEQ ID NO:21
gg. 90% identical to SEQ ID NO:23;
hh. 95% identical to SEQ ID NO:23;
ii. 98% identical to SEQ ID NO:23;
jj. SEQ ID NO:23
kk. 90% identical to SEQ ID NO:25;
ll. 95% identical to SEQ ID NO:25;
mm. 98% identical to SEQ ID NO:25; and
nn. SEQ ID NO:25.
19 . The method of claim 10 , wherein the ActRII inhibitor is a polypeptide comprising the amino acid sequence of SEQ ID NO:7.
20 . The method of claim 10 , wherein the ActRII inhibitor is administered parentally.
21 . The method of claim 10 , wherein the subject is less than 18 years old.
22 . The method of claim 10 , wherein the method increases the height of the subject.
23 . The method of claim 10 , wherein the subject has end stage renal disease.
24 . The method of claim 10 , wherein the subject undergoes dialysis.Join the waitlist — get patent alerts
Track US2019262423A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.